1. Home
  2. SNDX vs SEI Comparison

SNDX vs SEI Comparison

Compare SNDX & SEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • SEI
  • Stock Information
  • Founded
  • SNDX 2005
  • SEI 2014
  • Country
  • SNDX United States
  • SEI United States
  • Employees
  • SNDX N/A
  • SEI N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • SEI
  • Sector
  • SNDX Health Care
  • SEI
  • Exchange
  • SNDX Nasdaq
  • SEI NYSE
  • Market Cap
  • SNDX 1.1B
  • SEI 1.2B
  • IPO Year
  • SNDX 2016
  • SEI 2017
  • Fundamental
  • Price
  • SNDX $9.92
  • SEI $32.65
  • Analyst Decision
  • SNDX Strong Buy
  • SEI Strong Buy
  • Analyst Count
  • SNDX 11
  • SEI 8
  • Target Price
  • SNDX $34.00
  • SEI $43.43
  • AVG Volume (30 Days)
  • SNDX 1.7M
  • SEI 1.6M
  • Earning Date
  • SNDX 08-04-2025
  • SEI 07-23-2025
  • Dividend Yield
  • SNDX N/A
  • SEI 1.47%
  • EPS Growth
  • SNDX N/A
  • SEI N/A
  • EPS
  • SNDX N/A
  • SEI 0.62
  • Revenue
  • SNDX $43,722,000.00
  • SEI $446,975,000.00
  • Revenue This Year
  • SNDX $431.08
  • SEI $65.83
  • Revenue Next Year
  • SNDX $105.38
  • SEI $35.50
  • P/E Ratio
  • SNDX N/A
  • SEI $52.28
  • Revenue Growth
  • SNDX N/A
  • SEI 62.66
  • 52 Week Low
  • SNDX $8.58
  • SEI $10.96
  • 52 Week High
  • SNDX $23.37
  • SEI $39.03
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 51.66
  • SEI N/A
  • Support Level
  • SNDX $9.42
  • SEI N/A
  • Resistance Level
  • SNDX $10.75
  • SEI N/A
  • Average True Range (ATR)
  • SNDX 0.58
  • SEI 0.00
  • MACD
  • SNDX 0.08
  • SEI 0.00
  • Stochastic Oscillator
  • SNDX 51.74
  • SEI 0.00

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About SEI SOLARIS ENERGY INFRASTRUCTURE INC

Solaris Energy Infrastructure Inc provides services in the oil and gas industry. Its solutions are Solaris software suite, Fluid management system, Automated control systems, Field services, Last mile management, Wet sand solutions, Power Solutions, and Integrated wellsite solution. Its segment include Solaris Power Solutions and Solaris Logistics Solutions. It derives maximum revenue from Solaris Logistics Solutions segment.

Share on Social Networks: